Ilan Hadar
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Ilan Hadar
Ilan Hadar is recorded as CEO and Chairman at Silexion Therapeutics Corp (SLXN). Silexion Therapeutics Corp reported in an 8-K filed August 21, 2024 that Ilan Hadar was appointed Chairman, effective August 15, 2024. Silexion Therapeutics Corp reported in an 8-K filed August 21, 2024 that Ilan Hadar was appointed Chief Executive Officer, effective August 15, 2024. The proxy statement of Silexion Therapeutics Corp reports total compensation of $1,540,628 for Ilan Hadar in fiscal 2024, including a base salary of $240,560. Disclosed compensation is on record for 2 fiscal years.
“Pursuant to the appointment by New Silexion's shareholders prior to the Closing, the following persons constitute the Board effective upon the Closing: Ilan Hadar (Chairman), Dror Abramov, Ruth Alon, Ilan Levin, Avner Lushi, Shlomo Noy, and Ilan Shiloah.”
“Effective as of the Closing, the Board appointed Ilan Hadar, Mirit Horenshtein Hadar, CPA, and Dr. Mitchell Shirvan to serve as Chief Executive Officer, Chief Financial Officer, and Chief Scientific and Development Officer, respectively.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2024-08-15–present
-
Current
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Silexion Therapeutics Corp
Other people whose current roles at this company are on record from its filings.
- Mirit Horenshtein Hadar CFO
- Amnon Peled Board Member
- Avner Lushi Board Member
- Dror Abramov Board Member
- Ilan Levin Board Member
- Ilan Shiloah Board Member
- Ruth Alon Board Member
- Shlomo Noy Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Silexion Therapeutics Corp (SLXN) | Chief Executive Officer (formerly Managing Director of Silexion Israel) | $240,560 | $1,540,628 |
| 2023 | Silexion Therapeutics Corp (SLXN) | Chief Executive Officer (formerly Managing Director of Silexion Israel) | $182,976 | $253,614 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.